Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-10

Clinical Trial Update: Galcanezumab for Vestibular Migraine [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating galcanezumab for vestibular migraine has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Emgality (galcanezumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Vestibular Migraine | Phase 2 | Status: COMPLETED | Results posted: 2024-12-10